vs
Cardlytics, Inc.（CDLX）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是Cardlytics, Inc.的1.4倍（$69.8M vs $50.9M），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs -25.5%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs -9.6%）
Cardlytics是一家领先的购买智能与广告技术企业，与多家大型银行合作分析匿名消费者交易数据，为消费品牌、零售商及服务商提供基于真实消费行为的精准效果广告投放服务，核心业务覆盖北美与英国地区。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
CDLX vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.4倍
$50.9M
营收增速更快
RIGL
高出46.6%
-25.5%
两年增速更快
RIGL
近两年复合增速
-9.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $50.9M | $69.8M |
| 净利润 | — | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | -12.0% | 33.2% |
| 净利率 | — | 384.0% |
| 营收同比 | -25.5% | 21.2% |
| 净利润同比 | — | 1769.2% |
| 每股收益（稀释后） | $-0.15 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDLXRIGL
| Q4 25 | $50.9M | $69.8M | ||
| Q3 25 | $47.0M | $69.5M | ||
| Q2 25 | $58.0M | $101.7M | ||
| Q1 25 | $56.4M | $53.3M | ||
| Q4 24 | $68.3M | $57.6M | ||
| Q3 24 | $61.1M | $55.3M | ||
| Q2 24 | $64.0M | $36.8M | ||
| Q1 24 | $62.2M | $29.5M |
净利润CDLXRIGL
| Q4 25 | — | $268.1M | ||
| Q3 25 | $-72.7M | $27.9M | ||
| Q2 25 | $-9.3M | $59.6M | ||
| Q1 25 | $-13.3M | $11.4M | ||
| Q4 24 | — | $14.3M | ||
| Q3 24 | $-145.2M | $12.4M | ||
| Q2 24 | $-4.3M | $-1.0M | ||
| Q1 24 | $-24.3M | $-8.2M |
毛利率CDLXRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率CDLXRIGL
| Q4 25 | -12.0% | 33.2% | ||
| Q3 25 | -146.6% | 40.9% | ||
| Q2 25 | -22.0% | 60.1% | ||
| Q1 25 | -24.9% | 23.9% | ||
| Q4 24 | -12.2% | 28.9% | ||
| Q3 24 | -243.1% | 25.4% | ||
| Q2 24 | -24.7% | 1.2% | ||
| Q1 24 | -36.7% | -23.6% |
净利率CDLXRIGL
| Q4 25 | — | 384.0% | ||
| Q3 25 | -154.7% | 40.2% | ||
| Q2 25 | -16.0% | 58.6% | ||
| Q1 25 | -23.5% | 21.5% | ||
| Q4 24 | — | 24.9% | ||
| Q3 24 | -237.6% | 22.5% | ||
| Q2 24 | -6.7% | -2.8% | ||
| Q1 24 | -39.0% | -27.9% |
每股收益（稀释后）CDLXRIGL
| Q4 25 | $-0.15 | $14.11 | ||
| Q3 25 | $-1.36 | $1.46 | ||
| Q2 25 | $-0.18 | $3.28 | ||
| Q1 25 | $-0.26 | $0.63 | ||
| Q4 24 | $-0.36 | $0.82 | ||
| Q3 24 | $-2.90 | $0.70 | ||
| Q2 24 | $-0.09 | $-0.06 | ||
| Q1 24 | $-0.56 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $48.7M | $155.0M |
| 总债务越低越好 | $212.6M | $52.5M |
| 股东权益账面价值 | $-6.5M | $391.5M |
| 总资产 | $285.6M | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资CDLXRIGL
| Q4 25 | $48.7M | $155.0M | ||
| Q3 25 | $44.0M | $137.1M | ||
| Q2 25 | $46.7M | $108.4M | ||
| Q1 25 | $52.0M | $77.1M | ||
| Q4 24 | $65.6M | $77.3M | ||
| Q3 24 | $67.0M | $61.1M | ||
| Q2 24 | $71.2M | $49.1M | ||
| Q1 24 | $97.8M | $49.5M |
总债务CDLXRIGL
| Q4 25 | $212.6M | $52.5M | ||
| Q3 25 | $214.6M | $60.0M | ||
| Q2 25 | $214.3M | $60.0M | ||
| Q1 25 | $213.9M | $60.0M | ||
| Q4 24 | $213.6M | $60.0M | ||
| Q3 24 | $213.2M | $60.0M | ||
| Q2 24 | $212.9M | $60.0M | ||
| Q1 24 | $257.9M | $60.0M |
股东权益CDLXRIGL
| Q4 25 | $-6.5M | $391.5M | ||
| Q3 25 | $-4.7M | $117.6M | ||
| Q2 25 | $58.7M | $81.9M | ||
| Q1 25 | $64.1M | $18.6M | ||
| Q4 24 | $70.0M | $3.3M | ||
| Q3 24 | $69.7M | $-14.6M | ||
| Q2 24 | $210.0M | $-29.9M | ||
| Q1 24 | $199.1M | $-31.7M |
总资产CDLXRIGL
| Q4 25 | $285.6M | $513.6M | ||
| Q3 25 | $292.8M | $242.5M | ||
| Q2 25 | $361.1M | $206.7M | ||
| Q1 25 | $369.1M | $176.0M | ||
| Q4 24 | $392.7M | $164.0M | ||
| Q3 24 | $399.4M | $139.4M | ||
| Q2 24 | $534.4M | $128.4M | ||
| Q1 24 | $569.0M | $126.5M |
负债/权益比CDLXRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | 3.65× | 0.73× | ||
| Q1 25 | 3.34× | 3.23× | ||
| Q4 24 | 3.05× | 18.25× | ||
| Q3 24 | 3.06× | — | ||
| Q2 24 | 1.01× | — | ||
| Q1 24 | 1.29× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.0M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $13.0M | — |
| 自由现金流率自由现金流/营收 | 25.5% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | $8.8M | — |
8季度趋势，按日历期对齐
经营现金流CDLXRIGL
| Q4 25 | $13.0M | $22.0M | ||
| Q3 25 | $1.8M | $24.0M | ||
| Q2 25 | $1.2M | $30.5M | ||
| Q1 25 | $-6.7M | $-893.0K | ||
| Q4 24 | $3.0M | $14.5M | ||
| Q3 24 | $1.4M | $21.7M | ||
| Q2 24 | $4.4M | $302.0K | ||
| Q1 24 | $-17.6M | $-5.0M |
自由现金流CDLXRIGL
| Q4 25 | $13.0M | — | ||
| Q3 25 | $1.7M | — | ||
| Q2 25 | $903.0K | — | ||
| Q1 25 | $-6.8M | — | ||
| Q4 24 | $2.9M | — | ||
| Q3 24 | $878.0K | — | ||
| Q2 24 | $4.1M | — | ||
| Q1 24 | $-18.3M | — |
自由现金流率CDLXRIGL
| Q4 25 | 25.5% | — | ||
| Q3 25 | 3.7% | — | ||
| Q2 25 | 1.6% | — | ||
| Q1 25 | -12.1% | — | ||
| Q4 24 | 4.2% | — | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | 6.5% | — | ||
| Q1 24 | -29.4% | — |
资本支出强度CDLXRIGL
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.8% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 1.0% | — |
现金转化率CDLXRIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
